期刊
NATURE
卷 586, 期 7830, 页码 567-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41586-020-2622-0
关键词
-
资金
- Intramural Research Program of the VRC
- Division of Intramural Research, NIAID, NIH
- NIH NIAID [R01-AI127521, T32-AI007151]
- NIH [AI149644, AI100625, HHSN261200800001E, HHSN272201700036I, 75N93019F00132, 5494549]
- Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority [75A50120C00034]
- Undergraduate Scholarship Program, Office of Intramural Training and Education, Office of the Director, NIH
- Burroughs Wellcome Fund Postdoctoral Enrichment Program Award
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI005125, ZIAAI005152] Funding Source: NIH RePORTER
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity(1). This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant(2) SARS-CoV-2 as well as CD8(+) T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a phase III trial to evaluate its efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据